Seres Therapeutics’ SER-109 has faced more setbacks than most drugs, but the biotech has kept the faith and is now tantalizingly close to possibly seeing its candidate become the first FDA-approved oral microbiome therapeutic.

Clario, a clinical trial tech firm, has outlined three areas where artificial intelligence can improve patient experiences in the burgeoning landscape of decentralized clinical trials.

Merck KGaA has provided efficacy data from the open-label extension of its phase 2 trial in relapsing multiple sclerosis, delivering evidence of the durability of the effects of the BTK inhibitor evobrutinib.

Pacific Biosciences raised the curtain on two DNA sequencers: its first short-read device, designed to offer new competition to the industry giant Illumina, as well as a machine poised to be an upgrade over its current long-read hardware.

In less than a week, Ipsen’s rare genetic disorder drug was set to go be reviewed by FDA’s independent expert panel, but that timeline is now off.

BOSTON—Artificial intelligence is often seen as a “black box,” a scary concept that becomes even more so as the technology becomes increasingly embedded in the healthcare industry.

Existing HIV antiretroviral therapies are mostly small-molecule drugs that require daily medication. Broadly neutralizing antibodies (bNAbs) hold promise as potential longer-term options, and GSK’s ViiV Healthcare has provided encouraging early proof-of-concept data for such a candidate.

Donuts. Candy bars. Cinnamon rolls. These sweet treats are hardly necessary for survival, but, for many of us, they’re difficult to resist—even when we’re not hungry.

After a second patient death, Alpine Immune Sciences is terminating enrollment for two trials assessing its cancer asset davoceticept, including the biotech’s combo study with Merck’s Keytruda for adults with advanced malignancies.

A phase 3 failure puts another nail in the coffin for Tricida to get its kidney disease drug to market, two years after the FDA denied approval.